Clarifying off-target effects for torcetrapib using network pharmacology and reverse docking approach

BMC Systems Biology

Volumn 6, Issue , 2012, Pages

  Fan, Shengjun ^a   Geng, Qiang ^b   Pan, Zhenyu ^c   Li, Xin ^a   Tie, Lu ^a   Pan, Yan ^a   Li, Xuejun ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^c XI AN CHILDREN S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; MET PROTEIN, HUMAN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; QUINOLINE DERIVATIVE; SCATTER FACTOR RECEPTOR; TORCETRAPIB; TRANSCRIPTOME;

ARTICLE; CHEMISTRY; DRUG EFFECT; GENE REGULATORY NETWORK; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MOLECULAR DOCKING; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY;

GENE REGULATORY NETWORKS; HUMANS; INTERLEUKIN-2; MOLECULAR DOCKING SIMULATION; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS C-MET; QUINOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, INTERLEUKIN-2; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; TRANSCRIPTOME;

MLCS; MLOWN;

EID: 84872523213     PISSN: None     EISSN: 17520509     Source Type: Journal    
DOI: 10.1186/1752-0509-6-152     Document Type: Article

References (53)

1. Bays H, Stein EA. Pharmacotherapy for dyslipidaemia-current therapies and future agents. Expert Opin Pharmacother 2003, 4(11):1901-1938. 10.1517/14656566.4.11.1901, 14596646.
2. Assmann G, Gotto AJ. HDL cholesterol and protective factors in atherosclerosis. Circulation 2004, 109(23 Suppl 1):I8-I14.
3. Demarin V, Lisak M, Morovic S, Cengic T. Low high-density lipoprotein cholesterol as the possible risk factor for stroke. Acta Clin Croat 2010, 49(4):429-439.
4. Shinkai H. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases. Vasc Health Risk Manag 2012, 8:323-331. 3363149, 22661899.
5. Clark RW, Sutfin TA, Ruggeri RB, Willauer AT, Sugarman ED, Magnus-Aryitey G, Cosgrove PG, Sand TM, Wester RT, Williams JA, Perlman ME, Bamberger MJ. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 2004, 24(3):490-497. 10.1161/01.ATV.0000118278.21719.17, 14739125.
6. Barter PJ, Rye KA, Tardif JC, Waters DD, Boekholdt SM, Breazna A, Kastelein JJ. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the investigation of lipid level management to understand its impact in atherosclerotic events (ILLUMINATE) trial. Circulation 2011, 124(5):555-562. 10.1161/CIRCULATIONAHA.111.018259, 21804130.
7. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008, 4(11):682-690. 10.1038/nchembio.118, 18936753.
8. Kitano H. Systems biology: a brief overview. Science 2002, 295(5560):1662-1664. 10.1126/science.1069492, 11872829.
9. Kortagere S, Lill M, Kerrigan J. Role of computational methods in pharmaceutical sciences. Methods Mol Biol 2012, 929:21-48. 10.1007/978-1-62703-050-2_3, 23007425.
10. Xie L, Xie L, Bourne PE. Structure-based systems biology for analyzing off-target binding. Curr Opin Struct Biol 2011, 21(2):189-199. 10.1016/j.sbi.2011.01.004, 3070778, 21292475.
11. Chen YZ, Zhi DG. Ligand-protein inverse docking and its potential use in the computer search of protein targets of a small molecule. Proteins 2001, 43(2):217-226. 10.1002/1097-0134(20010501)43:2<217::AID-PROT1032>3.0.CO;2-G, 11276090.
12. Zhao S, Iyengar R. Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. Annu Rev Pharmacol Toxicol 2012, 52:505-521. 10.1146/annurev-pharmtox-010611-134520, 22235860.
13. Cui Q, Ma Y, Jaramillo M, Bari H, Awan A, Yang S, Zhang S, Liu L, Lu M, O'Connor-McCourt M, Purisima EO, Wang E. A map of human cancer signaling. Mol Syst Biol 2007, 3:152. 2174632, 18091723.
14. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003, 13(11):2498-2504. 10.1101/gr.1239303, 403769, 14597658.
15. Martin A, Ochagavia ME, Rabasa LC, Miranda J, Fernandez-de-Cossio J, Bringas R. BisoGenet: a new tool for gene network building, visualization and analysis. BMC Bioinforma 2010, 11:91.
16. Nepusz T, Yu H, Paccanaro A. Detecting overlapping protein complexes in protein-protein interaction networks. Nat Methods 2012, 9(5):471-472. 10.1038/nmeth.1938, 3543700, 22426491.
17. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4(1):44-57.
18. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009, 37(1):1-13. 10.1093/nar/gkn923, 2615629, 19033363.
19. Chen J, Bardes EE, Aronow BJ, Jegga AG. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res 2009, 37(Web Server issue):W305-W311. 2703978, 19465376.
20. Davidson E, Levin M. Gene regulatory networks. Proc Natl Acad Sci U S A 2005, 102(14):4935. 10.1073/pnas.0502024102, 556010, 15809445.
21. Tousoulis D, Davies G, Stefanadis C, Toutouzas P, Ambrose JA. Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart 2003, 89(9):993-997. 10.1136/heart.89.9.993, 1767836, 12923007.
22. Mottaghi A, Salehi E, Sezavar H, Keshavarz SA, Eshraghian MR, Rezaei N, Rejali L, Saboor-Yaraghi AA. The in vitro effect of oxidized LDL and PHA on proliferation and gene expression of regulatory T cells in patients with atherosclerosis. Iran J Allergy Asthma Immunol 2012, 11(3):217-223.
23. Dinh TN, Kyaw TS, Kanellakis P, To K, Tipping P, Toh BH, Bobik A, Agrotis A. Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4 + CD25 + Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis. Circulation 2012, 126(10):1256-1266. 10.1161/CIRCULATIONAHA.112.099044, 22851544.
24. Xiong YS, Wu AL, Lin QS, Yu J, Li C, Zhu L, Zhong RQ. Contribution of monocytes Siglec-1 in stimulating T cells proliferation and activation in atherosclerosis. Atherosclerosis 2012, 224(1):58-65. 10.1016/j.atherosclerosis.2012.06.063, 22789514.
25. Ammirati E, Monaco C, Norata GD. Antigen-dependent and antigen-independent pathways modulate CD4 + CD28 null T-cells during atherosclerosis. Circ Res 2012, 111(2):e48-e51. 10.1161/CIRCRESAHA.112.271627, 22773429.
26. Gotsman I, Sharpe AH, Lichtman AH. T-cell costimulation and coinhibition in atherosclerosis. Circ Res 2008, 103(11):1220-1231. 10.1161/CIRCRESAHA.108.182428, 2662382, 19028921.
27. El CH, Hassoun PM. Immune and inflammatory mechanisms in pulmonary arterial hypertension. Prog Cardiovasc Dis 2012, 55(2):218-228. 10.1016/j.pcad.2012.07.006, 23009917.
28. Morillas P, de Andrade H, Castillo J, Quiles J, Bertomeu-Gonzalez V, Cordero A, Tarazon E, Rosello E, Portoles M, Rivera M, Bertomeu-Martínez V. Inflammation and apoptosis in hypertension. Relevance of the extent of target organ damage. Rev Esp Cardiol 2012, 65(9):819-825. 10.1016/j.recesp.2012.03.020, 22771083.
29. Hernandez-Presa MA, Bustos C, Ortego M, Tunon J, Ortega L, Egido J. ACE inhibitor quinapril reduces the arterial expression of NF-kappaB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis. Am J Pathol 1998, 153(6):1825-1837. 10.1016/S0002-9440(10)65697-0, 1866315, 9846973.
30. Hoch NE, Guzik TJ, Chen W, Deans T, Maalouf SA, Gratze P, Weyand C, Harrison DG. Regulation of T-cell function by endogenously produced angiotensin II. Am J Physiol Regul Integr Comp Physiol 2009, 296(2):R208-R216. 2643984, 19073907.
31. Nataraj C, Oliverio MI, Mannon RB, Mannon PJ, Audoly LP, Amuchastegui CS, Ruiz P, Smithies O, Coffman TM. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Invest 1999, 104(12):1693-1701. 10.1172/JCI7451, 409880, 10606623.
32. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007, 204(10):2449-2460. 10.1084/jem.20070657, 2118469, 17875676.
33. Korpisalo P, Karvinen H, Rissanen TT, Kilpijoki J, Marjomaki V, Baluk P, McDonald DM, Cao Y, Eriksson U, Alitalo K, Ylä-Herttuala S. Vascular endothelial growth factor-A and platelet-derived growth factor-B combination gene therapy prolongs angiogenic effects via recruitment of interstitial mononuclear cells and paracrine effects rather than improved pericyte coverage of angiogenic vessels. Circ Res 2008, 103(10):1092-1099. 10.1161/CIRCRESAHA.108.182287, 18832750.
34. Yamamoto S, Fukumoto E, Yoshizaki K, Iwamoto T, Yamada A, Tanaka K, Suzuki H, Aizawa S, Arakaki M, Yuasa K, Oka K, Chai Y, Nonaka K, Fukumoto S. Platelet-derived growth factor receptor regulates salivary gland morphogenesis via fibroblast growth factor expression. J Biol Chem 2008, 283(34):23139-23149. 10.1074/jbc.M710308200, 18559345.
35. Cagnin S, Biscuola M, Patuzzo C, Trabetti E, Pasquali A, Laveder P, Faggian G, Iafrancesco M, Mazzucco A, Pignatti PF, Lanfranchi G. Reconstruction and functional analysis of altered molecular pathways in human atherosclerotic arteries. BMC Genomics 2009, 10:13. 10.1186/1471-2164-10-13, 2654039, 19134193.
36. Cha BY, Shi WL, Yonezawa T, Teruya T, Nagai K, Woo JT. An inhibitory effect of chrysoeriol on platelet-derived growth factor (PDGF)-induced proliferation and PDGF receptor signaling in human aortic smooth muscle cells. J Pharmacol Sci 2009, 110(1):105-110. 10.1254/jphs.08282FP, 19423953.
37. Li D, Ma S, Yang Y, Yang D, Li G, Zhang X, Zhu J, Sun M, Tang B. BTEB2 knockdown suppresses neointimal hyperplasia in a rat artery balloon injury model. Mol Med Report 2011, 4(3):413-417.
38. Shim AH, Liu H, Focia PJ, Chen X, Lin PC, He X. Structures of a platelet-derived growth factor/propeptide complex and a platelet-derived growth factor/receptor complex. Proc Natl Acad Sci U S A 2010, 107(25):11307-11312. 10.1073/pnas.1000806107, 2895058, 20534510.
39. Kim TJ, Lee JH, Lee JJ, Yu JY, Hwang BY, Ye SK, Shujuan L, Gao L, Pyo MY, Yun YP. Corynoxeine isolated from the hook of Uncaria rhynchophylla inhibits rat aortic vascular smooth muscle cell proliferation through the blocking of extracellular signal regulated kinase 1/2 phosphorylation. Biol Pharm Bull 2008, 31(11):2073-2078. 10.1248/bpb.31.2073, 18981576.
40. Chintalgattu V, Ai D, Langley RR, Zhang J, Bankson JA, Shih TL, Reddy AK, Coombes KR, Daher IN, Pati S, Patel SS, Pocius JS, Taffet GE, Buja LM, Entman ML, Khakoo AY. Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. J Clin Invest 2010, 120(2):472-484. 10.1172/JCI39434, 2810076, 20071776.
41. Hao L, Du M, Lopez-Campistrous A, Fernandez-Patron C. Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ Res 2004, 94(1):68-76. 10.1161/01.RES.0000109413.57726.91, 14656925.
42. Wang X, Huong SM, Chiu ML, Raab-Traub N, Huang ES. Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus. Nature 2003, 424(6947):456-461. 10.1038/nature01818, 12879076.
43. Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, Lee DC, Friedlander G, Terzi F. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med 2005, 11(8):867-874. 10.1038/nm1275, 16041383.
44. Baliga RR, Pimental DR, Zhao YY, Simmons WW, Marchionni MA, Sawyer DB, Kelly RA. NRG-1-induced cardiomyocyte hypertrophy. Role of PI-3-kinase, p70(S6K), and MEK-MAPK-RSK. Am J Physiol 1999, 277(5 Pt 2):H2026-H2037.
45. Nieder C, Andratschke N, Jeremic B, Molls M. Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer. Anticancer Res 2003, 23(6D):5117-5123.
46. Taniyama Y, Morishita R, Aoki M, Hiraoka K, Yamasaki K, Hashiya N, Matsumoto K, Nakamura T, Kaneda Y, Ogihara T. Angiogenesis and antifibrotic action by hepatocyte growth factor in cardiomyopathy. Hypertension 2002, 40(1):47-53. 10.1161/01.HYP.0000020755.56955.BF, 12105137.
47. Zhu Y, Hojo Y, Ikeda U, Shimada K. Production of hepatocyte growth factor during acute myocardial infarction. Heart 2000, 83(4):450-455. 10.1136/heart.83.4.450, 1729356, 10722550.
48. Morishita R, Nakamura S, Nakamura Y, Aoki M, Moriguchi A, Kida I, Yo Y, Matsumoto K, Nakamura T, Higaki J, Ogihara T. Potential role of an endothelium-specific growth factor, hepatocyte growth factor, on endothelial damage in diabetes. Diabetes 1997, 46(1):138-142. 10.2337/diabetes.46.1.138, 8971094.
49. Park JK, Mervaala EM, Muller DN, Menne J, Fiebeler A, Luft FC, Haller H. Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion. J Hypertens 2009, 27(3):599-605. 10.1097/HJH.0b013e32831ef369, 19262227.
50. Edgar R, Domrachev M, Lash AE. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002, 30(1):207-210. 10.1093/nar/30.1.207, 99122, 11752295.
51. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001, 98(9):5116-5121. 10.1073/pnas.091062498, 33173, 11309499.
52. Mestres J, Knegtel RMA. Similarity versus docking in 3D virtual screening. Perspect Drug Des Discov 2000, 20:191-207.
53. Wu G, Robertson DH, Brooks CR, Vieth M. Detailed analysis of grid-based molecular docking: a case study of CDOCKER-A CHARMm-based MD docking algorithm. J Comput Chem 2003, 24(13):1549-1562. 10.1002/jcc.10306, 12925999.